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Original Article
The Patient Burden of Screening Mammography Recall
Matthew Alcusky, PharmD, MS,1 Liane Philpotts, MD, FSBI,2 Machaon Bonafede, PhD, MPH,3
Janice Clarke, RN, BBA,1 and Alexandria Skoufalos, EdD1
Abstract
Objective: The aim of this article is to evaluate the burden of direct and indirect costs borne by recalled patients
after a false positive screening mammogram.
Methods: Women aged 40–75 years undergoing screening mammography were identified from a U.S. com-
mercial claims database. Women were required to have 12 months pre- and 6 months post-index enrollment to
identify utilization and exclude patients with subsequent cancer diagnoses. Recall was defined as the use of
diagnostic mammography or breast ultrasound during 6 months post-index. Descriptive statistics were presented
for recalled and non-recalled patients; differences were compared using the chi square test. Out-of-pocket costs
were totaled by utilization type and in aggregate for all recall utilization.
Results: Of 1,723,139 patients with a mammography screening that were not diagnosed with breast cancer,
259,028 (15.0%) were recalled. Significant demographic differences were observed between recalled and non-
recalled patients. The strongest drivers of patient costs were image-guided biopsy (mean $351 among 11.8%
utilizing), diagnostic mammography ($50; 80.1%), and ultrasound ($58; 65.7%), which accounted for 29.9%,
29.0%, and 27.5% of total recall costs, respectively. For many patients the entire cost of recall utilization was
covered by the health plan. Total costs were substantially greater among patients with biopsy; one-third of all
patients experienced multiple days of recall utilization.
Conclusion: After a false positive screening mammography, recalled women incurred both direct medical costs
and indirect time costs. The cost burden for women with employer-based insurance was dependent upon the
type of utilization and extent of health plan coverage. Additional research and technologies are needed to
address the entirety of the recall burden in diverse populations of women.
Introduction
Breast cancer is the second leading cause of cancerdeath and the most common non-skin-related cancer in
women.1 Screening mammography is used to detect pre-
symptomatic breast cancers, providing the opportunity for
earlier intervention with the goal of reducing breast cancer–
related mortality.2–4 Relative risk reductions in mortality
from mammography screening have been estimated to be
approximately 20% based upon the results of randomized
trials involving over 650,000 women in North America and
Europe.5–6 Retrospective analysis of population based United
States registry data from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results program de-
termined that, after adjustment for underlying temporal
trends, the incidence of late-stage breast cancer has decreased
37% and early-stage disease incidence has increased 48%
during the mammography screening era.7 The magnitude and
direction of mammography’s net effect remains highly con-
tested;8 the applicability of older randomized trials must be
interpreted in the context of evolving treatment paradigms
and balanced with potential harms in the form of false posi-
tives, overdiagnosis, and overtreatment.
In the United States, guidelines for breast cancer screening
practices are not systematically updated across societies and
groups. The most recent guidelines available from the
American Cancer Society and the American College of Ob-
stetricians and Gynecologists recommend the annual
screening of women at average risk beginning at age 40.2,3
These guidelines acknowledge the importance of the indi-
vidualization of screening based upon the risk profile and
preferences toward benefits and harms of screening of each
patient. The United States Preventive Services Taskforce
(USPSTF) released updated recommendations for breast
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cancer screening in 2009 that narrowed the target population
for biennial mammography screening to women between the
ages of 50 and 75.4 The USPSTF asserts that despite similar
benefits of screening in women ages 40–49, decreased cancer
incidence and an accompanying larger number needed to
screen contributes to a smaller net benefit in this population.4
Real-world data is useful to inform policy determinations,
as the actual screening compliance and interval between
screening mammograms varies considerably.9 Organizations
within and outside of the United States have provided largely
overlapping screening recommendations with certain dis-
tinctions, including triennial screening in the United King-
dom, that further emphasize the differential approach to
nationally supported screening programs and interpretation
of evidence surrounding mammography screening.10,11
Following a finding on a screening mammogram, the use
of further diagnostic processes to investigate an inconclusive
screening result (patient recall) appears to impact patients
unequally.12,13 Unnecessary recall, also referred to as a false
positive result, occurs when an initial screening result is
followed by further diagnostic procedures and utilization that
ultimately resolves with a benign outcome. The burden of
unnecessary recall on the patient and health care system will
vary as a function of the number, type, and associated cost of
follow-up procedures required to rule out a diagnosis of
breast cancer.13–17 Direct medical costs to the patient are de-
pendent upon the presence and type of health insurance.18–20
Adverse physical or psychological effects experienced by
some patients as a result of a false positive may amplify the
burden.21–22 False positives have been associated with short-
term increases in anxiety15 and with temporary decrements
in quality of life measures.22 Breast cancer–related anxiety
may last up to 3 years after the false positive recall has been
resolved.23 Indirect costs to patients secondary to missed
work time and lost productivity to employers due to pre-
senteeism and absenteeism must also be considered. Recalled
patients are required to schedule and travel to attend office
visits and undergo procedures, often accompanied by a com-
panion whose time also incurs an additional indirect cost.14,24
Additional time and travel costs for patients and their com-
panions, and the cost of securing substitute caregivers
(childcare and/or elder care, if applicable) associated with
participation in a cervical cancer screening program in the
United Kingdom have been estimated at 26% and 33% above
direct medical costs.24
Risks associated with false positives inherent within a
population-based screening approach are important consid-
erations in the use of mammography for early detection of
breast cancer. The risk of a false positive result from a
screening mammogram has been estimated using nation-
ally representative registry data from the National Cancer
Institute–funded Breast Cancer Surveillance Consortium.12
The probability of a false positive was approximately 16% at
an individual’s first screening mammogram and 10% at
subsequent screening mammograms.12 The cumulative risk
of a false positive result after 10 years of screening mam-
mograms was 61% for annual and 42% for biennial screen-
ing.12 Although the majority of false positives will prompt
further imaging, the cumulative probability of biopsy after 10
years of annual or biennial mammography screens is ap-
proximately 7.8% and 4.8% respectively.12 Accumulated
direct medical costs from recall-induced utilization are an-
ticipated to affect total health care expenditures. One study
that evaluated costs to the health plan estimated that for every
$100 spent on mammography screening and clinical breast
exams an additional $33 was spent evaluating false positive
results.13
Limited research has been conducted to evaluate the en-
tirety of the patient burden due to recall following a false
positive mammogram. In this study, we analyzed commercial
claims data for a population of women with employer-based
insurance to characterize patient costs associated with diag-
nostic pathways initiated due to unnecessary recall following
an inconclusive screening mammography result.
Methods
Patient selection
The Truven Health MarketScan Commercial and Medicare
Supplemental Databases were used to identify women aged
40–75 years undergoing screening mammography (index
event, Current Procedural Terminology [CPT] Code G0202)
from January 2011 to June 2013. Women were required to
have 12 months pre- and 6 months post-index continuous
enrollment, thus the study period encompassed January 1,
2010 to December 31, 2013. The Commercial and Medicare
Supplemental databases contain medical claims, pharmacy
claims, and enrollment data for approximately 38 million
covered lives in the working population and 3 million retirees
in 2012, respectively. Major data contributors include em-
ployers and health plans that cover employees and their de-
pendents through a variety of insurance plan structures
including under fee-for-service, fully capitated, and partially
capitated health plans (preferred provider organizations and
health maintenance organizations). The Medicare Supple-
mental database is representative of the national commer-
cially insured population of those individuals who have both
Medicare coverage and supplemental employer-sponsored
coverage. The patient data used in this analysis was de-
identified in compliance with the Health Insurance Portability
and Accountability Act regulations.
The date of the first screening mammogram during the
study period was designated as the index date for each pa-
tient. Women with any breast cancer screening, breast im-
aging procedure, or breast cancer diagnosis in the 12-month
pre-index period were excluded. Similarly, women with a
breast cancer diagnosis in the 6 months following the index
screening mammogram were excluded from the recall anal-
ysis. Demographic characteristics (age, geographic region,
health plan type) were defined on the index date.
Recall definition
Clinically, recall is determined using Breast Imaging Re-
porting and Data System (BI-RADS) scores to represent the
percent of women recommended for additional diagnostic
procedures following a screening mammogram. This analysis
utilized an administrative claims database that lacks radi-
ology reports and BI-RADS scores. Recall was defined as the
utilization of imaging in the 6 months following the index
screen; specifically, recall was defined as the receipt of a
diagnostic mammogram (CPT codes G0204, G0206, 77055,
77056) or a breast ultrasound procedure (CPT code 76645).
Other procedures that may follow imaging, such as biopsy or
S-12 ALCUSKY ET AL.
fine needle aspiration, were not required to meet the recall
definition. The number of patient-days associated with a re-
call was defined as the number of distinct calendar days in
which a patient had a recall-related event.
Patient out-of-pocket cost was the sum of patient copay-
ment and coinsurance costs for all breast-related diagnostic
services including the following: breast-related imaging
procedures in the 6 months following the index screen (e.g.,
diagnostic mammography, ultrasound, magnetic resonance
imaging [MRI], ductogram, computer-aided detection),
breast-related biopsy procedures and related expenses (e.g.,
anesthesiology and pathology), and outpatient office visits
with an abnormal mammogram diagnosis code or a breast-
related diagnosis. Breast cancer treatment costs were not
included in patient recall cost calculations, nor were patient
insurance premiums or any costs borne by the health plan.
Additional expenses realized by the patient (e.g., time off
work, childcare, transportation) were not included. All costs
are in 2013 US$, adjusted using the Medical Care Component
of the Consumer Price Index.
Descriptive statistics were calculated for demographic
characteristics of patients with and without recall and are
presented as frequencies and percentages. Differences be-
tween groups were compared using the chi-square test.
Means and standard deviations were computed for costs
among utilizers and among all patients for each specific
type of recall utilization. Costs among patients with non-zero
costs were also reported, with non-zero costs defined as oc-
curring when the health plan did not cover all charges and the
patient was responsible for a portion of the cost. Total mean
and median recall costs were also reported among all recalled
patients and those with non-zero cost, as well as for patients
with biopsy and stratified by age cohort. Finally, the total
number of distinct days with recall-associated utilization was
presented as frequencies and percentages of patients to de-
note the indirect cost of time for patients, companions, and
substitute caregivers.
Results
Of the 7,523,729 women who underwent a screening
mammogram between January 1, 2010 and December 31,
2013, 6,963,021 met the age criteria. A total of 1,754,363
women met the enrollment criteria for inclusion, of whom
31,224 patients with a breast cancer claim were excluded.
The study sample comprised 1,723,139 women without a
breast cancer claim during the 18-month study period, of
whom 259,028 (15.0%) met the definition for recall during
the 6-month post-index period (Table 1).
Demographics
The majority of the women in this study were between 50
and 64 years of age (54.6%), with the remainder of the
population largely consisting of women ages 40 to 49 years
(41.5%). Recalled patients were younger than those without
recall; 49.5% of recalled patients were in the youngest age
cohort (40–49 years) compared with 40.1% ( p < 0.001) of
women without recall. Approximately one-sixth (15.2%) of
Table 1. Demographic Characteristics of Patients With and Without Unnecessary Recall Following
the Index Screening Mammogram (N = 1,723,139) and the Recall Rate for Strata of Each Demographic
Characteristic
Patients with
recall n (%)
Patients without
recall n (%) p-value
Recall rate by
demographic subgroupa
Total population screened 259,028 (100.0) 1,464,111 (100.0) 15.0%
Age (years)
40–49 128,299 (49.5) 587,429 (40.1) < 0.001 17.9%
50–64 121,997 (47.1) 818,294 (55.9) 13.0%
65–75 8,732 (3.4) 58,388 (4.0) 13.0%
Region
Northeast 17,620 (6.8) 65,594 (4.5) < 0.001 21.2%
West 40,812 (15.8) 271,362 (18.5) 13.1%
South 93,729 (36.2) 549,383 (37.5) 14.6%
Midwest 56,568 (21.8) 366,766 (25.1) 13.4%
Mid-Atlantic 46,980 (18.1) 192,028 (13.1) 19.7%
Other/Unknown 3,319 (1.3) 18,978 (1.3) 14.9%
Health Plan Type
PPO 145,415 (56.1) 820,395 (56.0) < 0.001 15.1%
HMO 36,226 (14.0) 217,092 (14.8) 14.3%
POS 23,245 (9.0) 125,465 (8.6) 15.6%
CDHP/HDHP 22,913 (8.8) 128,623 (8.8) 15.1%
Comprehensive 7,165 (2.8) 44,179 (3.0) 14.0%
EPO 5,479 (2.1) 21,151 (1.4) 20.6%
Other/unknown 18,585 (7.2) 107,206 (7.3) 14.8%
Location of Residence
Rural 33,619 (13.0) 228,889 (15.6) < 0.001 12.8%
Nonrural 225,409 (87.0) 1,235,222 (84.4) 15.4%
aThe number of patients recalled in a demographic subgroup divided by the total number of patients in that subgroup.
CDHP/HDHP, consumer driven health plan/high deductible health plan; EPO, exclusive provider organization; HMO, health
maintenance organization; POS, point of service; PPO, preferred provider organization.
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the screened population, and a slightly smaller percentage
of the recalled patients (13.0%, p< 0.001), were identified as
residing in a rural area. The geographic distribution of the
screened population reflected the locations of employers and
health plans constituting the Truven Health MarketScan
Research databases, with the majority of the study population
living in the South (37.3%), followed by the Midwest
(24.6%) and the West (18.1%). Differences in region of
residence among patients with and without recall were sig-
nificant ( p < 0.001). Overall, the most common health plan
type was preferred provider organization (56.0%), with
health maintenance organization (14.7%) being the only
other plan type covering greater than 9% of the population.
Although the proportion of patients enrolled in each plan type
was largely consistent, the distribution of women with and
without recall among plan types was statistically significant.
The recall rate is reported for each level of demographic
variables in Table 1. The recall rate was greatest in younger
women aged 40–49 years (17.9%), compared with a consis-
tent rate of 13% in both older age cohorts. Variability in recall
rate was observed across geographic regions, with the largest
recall rates in the Northeast (21.2%) and Mid-Atlantic
(19.7%) and the lowest rates in the West (13.1%) and Mid-
west (13.4%). Patients residing in rural areas were recalled
less frequently (12.8%) compared with non-rural residents
(15.4%). Recall rates across health plan types ranged from a
minimum of 14.0% for comprehensive plans to a maximum
of 20.6% for exclusive provider organization (EPO) plans.
With the exception of EPO plans, all plan types had a recall
rate of 15.6% or less.
Frequency and cost of utilization following
unnecessary recall
Diagnostic mammography was the most common type of
recall-associated utilization (80.1%), accounting for 29.0%
of costs in this sample of recalled women (Table 2). Ultra-
sound was employed during the recall process for 65.7% of
women, and computer-aided detection was used for 39.9%,
constituting 27.5% and 2.1% of the total patient recall cost
respectively. Image-guided biopsy ($351) and open biopsy
($252) were the most expensive utilization types on a per
procedure basis, but due to infrequent utilization open bi-
opsy accounted for only 2.4% of total recall costs. Com-
paratively, image-guided biopsy was the largest driver of
total patient recall costs (29.9%) despite use in only 11.8% of
recalled patients. Ductogram ( < 0.1%), fine needle aspira-
tion (1.9%), and MRI (1.3%) were utilized infrequently, and
these procedures together accounted for less than 3% of total
recall cost.
The costs borne by patients for diagnostic imaging, pro-
cedure(s), and breast-related office visit utilization varied
substantially among patients within a type of utilization as
well as between different types of utilization. The variation
within a utilization type is best illustrated by the marked
divergence in cost burden observed when comparing patients
with non-zero cost to the cost among all patients with that
specific utilization type. Proportionally, this difference in
cost was greatest for utilizers of diagnostic mammography
for whom the mean cost was $50 among all utilizers and $97
among those with non-zero cost, a 94.0% increase. The
smallest proportional difference was a 10.2% increase ($49
vs. $54) for patients with non-zero costs for breast-related
outpatient office visits. The largest dollar value increase was
$120 for MRI ($187 vs $307). Among patients with non-zero
cost, the mean patient costs were substantially greater than
median costs consistently across all utilization types. The
larger cost difference between the median and 75th percentile
relative to the median and 25th percentile further demon-
strated the positive skew among patients with non-zero costs.
The total patient cost associated with utilization after un-
necessary recall was influenced by the utilization of services
by patients without any cost burden for such services (Table
3). The mean (standard deviation) total patient cost among all
recalled patients was $137.98 ($303.24), while the mean total
among patients with a non-zero cost was 49.8% greater
[$206.71 ($351.49)]. Recalled patients requiring a biopsy
bore a larger mean total cost [$448.65 ($636.97)]. More than
a quarter of the overall and age-stratified populations of re-
called patients were not responsible for any direct utilization
costs. The mean total patient costs were similar in patients
ages 40 to 49 [$145.40 ($303.24)] compared with those ages
50 to 64 [$134.74 ($298.99)], but the total cost was less among
patients 65 to 75 years of age [$74.33 ($162.47)]. Patient costs
associated with all-cause outpatient office visits, laboratory
services, pharmaceuticals, and mental health office visits were
consistent during the 6 months prior to the index screening
mammogram compared with the 6 months afterwards.
Table 3. Total Patient Costs of Diagnostic Imaging, Procedure, and Office Visit Utilization
Associated with Unnecessary Recall Following the Index Screening Mammogram
Statistic Mean (SD)a Mediana
25th
percentilea
75th
percentilea
Average patient cost for recallb $137.98 ($303.24) $33.67 $0.00 $152.81
Average cost among patients with non-zero costb $206.71 ($351.49) $95.38 $33.39 $240.81
Average cost among patients having received a biopsyb $448.65 ($636.97) $223.62 $41.58 $613.45
Average patient costs for recall by age cohortb (years)
40–49 $145.40 ($303.24) $36.52 $0.00 $164.35
50–64 $134.74 ($298.99) $32.04 $0.00 $147.96
65–75 $74.33 ($162.47) $25.93 $0.00 $80.11
aCosts expressed in 2013 United States dollars.
bAverage cost includes diagnostic imaging, procedures, and breast-related office visits associated with recall.
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Number of days with recall-associated utilization
Recall induces further utilization that requires time and
may occur on one or more days after the index screening
mammogram. Of all recalled patients, 33.3% had at least
two days with recall utilization, 11.7% had at least three days,
and 5.1% had four or more with recall utilization (Table 4).
Fewer women in the youngest cohort (ages 40–49 years) had
multiple days with recall utilization (28.9%) compared
with women ages 50–64 (36.9%) and ages 65–75 (44.6%).
Similarly, only 0.7% of women in the youngest age cohort
had greater than five days with recall utilization, relative to
1.1% of women ages 50–64 years and 1.4% of women ages
65–75.
Discussion
The financial burden to patients from health care utiliza-
tion due to unnecessary recall following a screening mam-
mogram was found to be significant and disproportionately
distributed. Although the study population encompassed only
women insured through an employer, variability in coverage
and utilization of recall-related procedures created substan-
tial disparities in costs borne by the patient. More than one-
quarter of all recalled patients incurred no utilization costs, in
contrast to hundreds of dollars borne among patients with
non-zero costs and several hundred dollars among patients
with biopsy. This imbalance is evident in the large standard
deviations associated with individual procedure and total
utilization costs (i.e., a marked number of patients who un-
derwent a biopsy sustained costs in excess of $1,000).
However, computed values of direct utilization costs only
partially explain the aggregate burden of recall, as the en-
tirety of the patient burden is reflected through a combination
of direct, indirect, and intangible costs. The opportunity cost
of time, incurred expenses for travel, and emotional impact of
an imminent diagnosis were not borne exclusively by the
patients who paid for health care utilization. Rather, these
costs are distributed nonuniformly across the entire popula-
tion of recalled patients.
Costs to patients associated with unnecessary recall have not
been extensively reported in the breast cancer screening lit-
erature. Analysis of the 2000 National Health Interview Study
indicated that the majority of women were not responsible for
out of pocket expenses for screening mammograms, specifi-
cally 68% of women aged 40–64 and 85% of women over age
65.19 More recently, the average patient cost for a mammo-
gram was estimated to be $33 (2007–2008 US$), constituting
14.1% of the $266 total mammography expense.18 This is
consistent with the $40 average cost we identified among all
recalled patients for diagnostic mammography.
A multi-community study in Florida evaluated patient re-
ported direct and indirect costs of screening, diagnosis, and
treatment among women who underwent a breast biopsy and
were ultimately diagnosed with benign breast disease or
breast cancer.14 Average patient costs (unadjusted for infla-
tion, 1991$ to 1995$) for diagnostic mammogram ($33) and
ultrasound ($15) were small, with a larger mammography
cost ($82) reported among uninsured women. Patients diag-
nosed with benign breast disease on average reported
spending 9 hours at appointments and, as a result of recall,
traveling a total mean distance of 56 miles.14
Although the administrative claims database used in this
analysis does not contain costs pertaining to travel and time,
the number of distinct days with recall utilization conveyed
the significant time burden among women. This burden di-
rectly translates into reduced productivity among employed
women undergoing recall utilization procedures along with
those who may provide companion care. Yabroff and col-
leagues found substantially increased annual time costs as-
sociated with medical care in cancer survivors (age 18–64
years, $500.28; age ‡ 65, $912.96) compared with individ-
uals without a cancer history (age 18–64, $225.97; age ‡ 65,
$606.91).25 These estimates were obtained using national
level time and cost estimates from national survey data
(Medical Expenditure Panel Survey, National Ambulatory
Medical Care Survey, National Hospital Ambulatory Medi-
cal Care Survey, National Health Interview Survey), the
Bureau of Labor Statistics median hourly wage rate of
$16.57, and the hourly value of home production of $5.32 per
hour.25 Use of these values in conjunction with travel and
outpatient visit times (travel, urban/rural: 35/39 minutes;
visit, urban/rural: 52/53 minutes) would likely estimate
greatly increased time costs for recalled patients. A third of
the recalled population in our study had multiple days with a
recall-related procedure, which may translate into multiple
days of costs and opportunity costs for the patient and com-
panion.
Additional relevant costs to patients such as premiums
and deductibles were not available for evaluation, but the
contribution of such costs to the patient burden should be
Table 4. Number of Days with Recall Associated Utilization in Patients Recalled
Unnecessarily after the Index Screening Mammogram by Age Cohort
Number of days
with a recall procedurea
All recalled
patients N (%)
Age 40–49
n (%)
Age 50–64
n (%)
Age 65–75
n (%)
1 dayb 259,028 (100.0) 128,299 (100.0) 121,997 (100.0) 8,732 (100.0)
2 days 55,849 (21.6) 25,570 (19.9) 27,983 (22.9) 2,233 (25.6)
3 days 17,198 (6.6) 6,791 (5.3) 9,462 (7.8) 892 (10.2)
4 days 7,466 (2.9) 2,707 (2.1) 4,288 (3.5) 441 (5.1)
5 days 3,394 (1.3) 1,184 (0.9) 1,983 (1.6) 212 (2.4)
> 5 days 2,317 (0.9) 852 (0.7) 1,337 (1.1) 119 (1.4)
aThe number of distinct calendar days with a recall-specific procedure.
bAll patients had at least 1 day with a recall-associated utilization as defined in the inclusion criteria.
S-16 ALCUSKY ET AL.
noted. In 2013, the average annual premium contribution
among workers with employer sponsored insurance was $999
for single coverage, while the average deductible amount for
single coverage was $1,135.26 These costs are not insignifi-
cant, and have increased markedly over the preceding decade.
The transition from patient to health care consumer in the
United States is being facilitated by increasing transparency of
health care costs and is evidenced by growing enrollment in
consumer-directed health plans.26 Financial incentives asso-
ciated with high deductible plans and increased out-of-pocket
costs have the potential to influence patient behavior,27 po-
tentially manifesting as changes in screening frequency or
redirection of volume to high quality providers and services
with leading cancer detection rates and lower rates of recall.
The national recall rate in the United States has been es-
timated to be above recommended performance benchmarks
and more than double rates reported in the United King-
dom.28 The estimated national cost of screening mammo-
graphy in 2010 was $6.2 billion, with the cost of recall
utilization (i.e., imaging and biopsies from true and false
positives) responsible for an additional $1.6 billion.29 The
claims-based recall rate of 15% in the present study exceeds
the recommended clinical performance benchmark of 10%,30
and the discrepancy would be even greater if patients with
true positive breast cancers had also been included. It follows
that a reduction in the burden of recall on the patient and the
health care system can be achieved most effectively through a
reduction in the proportion of patients recalled.
Multiple approaches to accomplishing the goal of de-
creasing recall have been proposed and evaluated. Decreas-
ing the frequency of screening and individualizing screening
recommendations based upon age and risk (as outlined in the
USPSTF guidelines) has been suggested to increase screen-
ing coverage while reducing the composite cost of screening
and recall.29 Alternative interventions have utilized double
reading and additional radiologist training with variable
success. Breast tomosynthesis is approved by the U.S. Food
and Drug Administration and has been demonstrated to re-
duce recall while increasing cancer detection in large mul-
tisite populations of women.31 A 13-site study of academic
and nonacademic centers in the United States compared 2-D
digital mammography with 3-D breast tomosynthesis. The
recall rate per 1,000 screens was 15% less for patients
screened with tomosynthesis (91 per 1,000; 95% confidence
interval [CI] 73–108) compared with digital mammography
(107 per 1,000; 95% CI 89–124). An increased cancer de-
tection rate was also observed with tomosynthesis (5.4 per
1,000;, 95% CI 4.9–6.0) relative to digital mammography
(4.2 per 1,000; 95% CI 3.8–4.7).31 A prior cost analysis
conducted using the Truven Health MarketScan Commer-
cial and Medicare Supplemental Databases modeled health
plan cost reductions as a result of reducing recall rates from
13.6% to less than 10% (using a 30%–40% range of previ-
ously reported recall rate reductions).16,32–36 The analysis
demonstrated potential savings per patient screened between
$50 and $67, assuming an incremental cost of $50 per
screening.16
Direct and indirect cost savings from reduced recall with
breast tomosynthesis would be expected to reduce the patient
burden. A relative reduction in the recall rate of similar
magnitude to that achieved in the recent tomosynthesis study
by Friedewald and colleagues31 would result in a larger ab-
solute recall reduction in our real-world population but would
still fall short of the established 10% clinical performance
standard. However, extrapolations of results from mammo-
graphy studies are limited by inter-professional variability in
mammographic expertise and preferences towards improved
cancer detection versus fewer false positives. Further evi-
dence of real-world usage and longer term follow-up is
necessary to fully characterize the sensitivity, specificity and
the impact on important health outcomes of this new tech-
nology.
This study has several limitations. Patients with breast
cancer that did not have a diagnosis claim within the 6-month
period after the index mammography screening may have
been misclassified as unnecessary screening recalls. This
potential source of bias is reduced by inclusion of costs from
recall utilization, without inclusion of costs of breast cancer
treatment, in the measure of patient burden. The use of di-
agnostic imaging necessary to be identified as recalled in our
study most closely approximated BI-RADS definitions of
recall; however, in rare circumstances it may have led to an
underreporting of recall due to misclassification of patients
that were in fact recalled but went directly to MRI, biopsy, or
fine needle aspiration without diagnostic imaging. Also, pa-
tients undergoing screening ultrasound following a screening
mammogram (due to dense tissue) may have been mis-
classified as recalled unnecessarily, which could have artifi-
cially inflated the recall rate.
Additional limitations were present due to the inability of
claims data to provide information on indirect costs and in-
tangible costs relating to time, travel, and psychological
consequences of recall. The analysis also did not include
insurance premiums and could not account for where patients
were in regards to meeting their annual deductible or other
cost sharing arrangements. This information would have
been valuable in further characterizing differences between
patients for whom the health plan covered the entire cost of
recall utilization, and patients with out- of-pocket costs. Fi-
nally, the patients in this study were commercially insured
and the results of this study do not reflect costs to uninsured
patients or those covered by other insurance programs, such
as Medicaid, full Medicare, or Veteran’s Affairs. Socio-
economic, ethnic, and racial factors have been shown to in-
fluence care patterns following abnormal mammography
screening results37 but were not assessable in the commercial
claims database.
Conclusion
The patient cost burden associated with recall after a false
positive screening mammogram was considerable, approxi-
mately $138 among all recalled women and $449 among
those who underwent a biopsy. More than a quarter of re-
called patients were not responsible for any direct costs,
contributing to large variability in cost burden as a result of
health plan coverage. All patients were subject to the burden
of indirect costs and associated time spent in recall. Sub-
stantial divergence in cost burden and a recall rate of 15%
was found in this population of women with insurance
through an employer. The impact of recall on diverse popu-
lations of women requires further investigation and should
include characterization of the indirect and intangible costs
associated with a false positive screening result. Ultimately,
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the patient burden from unnecessary recall will most effec-
tively be reduced through interventions and technologies
intended to decrease the incidence of false positives, therein
reducing the recall rate and subsequent costs to patients and
the health care system.
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